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Background: Very little is known about the relationship between spontaneous and
treatment-induced motor syndromes in Africans with first episode schizophrenia.
Objective: We investigated the association between spontaneous NSS and EPS, with
treatment-induced EPS in a homogenous sample of Black Africans with first episode
schizophrenia.
Methods: We examined Xhosa (South Africa) and Yoruba (Nigeria) patients, using
the Neurological Evaluation Scale and extrapyramidal symptoms scale before and at
3 months after exposure to low dose flupenthixol decanoate. Pearson’s correlations and
Linear regression models, controlling for duration of untreated psychosis (D.U.P) and
premorbid adjustments, were used in examining associations.
Results: Among 99 participants in the baseline sample, 91 (91.8%) and 20 (20.2%)
had at least one definite NSS and EPS, respectively, before exposure to antipsychotics.
Treatment-induced EPS were recorded in 34 (38.6%). Spontaneous EPS was associated
with treatment-emergent Akathisia in participants with a longer D.U.P (r = 0.75, β= 0.70,
p= 0.008). This association was specific for Parkinsonism (r = 0.75, β= 0.85, p= 0.008)
and dyskinesia (r = 0.75, β = 1.70, p = 0.008).
Conclusion: Similar to previous findings for tardive dyskinesia in studies implementing
longer-term follow-up, spontaneous EPS may also predict short-term antipsychotic-
induced EPS such as akathisia. These results may be important for early identification
of patients at risk of treatment-induced Akathisia-linked psychomotor agitation in first
episode schizophrenia.
Keywords: neurological examination, side effects, neurodevelopmental defects, locomotor control, tardive
dyskinesia, African ancestry
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INTRODUCTION
Early descriptions of schizophrenia include a broad spectrum of
neurological examination abnormalities (1) such as Neurological
soft signs (NSS) (2) and extrapyramidal syndromes (EPS) (3).
Yet, the introduction of antipsychotics has led to a universal
tendency to associate EPS with side effects (4) and NSS with
neurodevelopmental defects (5).
In other perspective, NSS and EPS are two extremes in the
diversity of neuromotor abnormalities in schizophrenia (6) [as
NSS are subtle, but demonstrable, impairment in the ability
to perform several motor and sensory tests on neurological
examination (7), and EPS the more obvious abnormalities
of locomotor control, involuntary movements, muscle tone,
posture, and support (8)]. Spontaneous motor syndromes has
emerged as a useful descriptor for signs (NSS and EPS) occurring
before first exposure to antipsychotics (3, 9).
To date, the three cross-sectional studies of the relationship
between NSS and treatment-emergent EPS in never-medicated
first-episode schizophrenia have reported conflicting findings
(10–12). However, a previous finding of an association between
baseline NSS and subsequent development of tardive dyskinesia
(TD) (13), across 24 months observation of a multiracial African
sample is profoundly important for the prevention of EPS
in susceptible patient populations. In this regard, some prior
studies conducted in other multiracial samples suggest that
persons of African ancestry may have a higher latent risk for
motor syndromes (3, 14, 15). Yet, very little is known about
the relationship between spontaneous and treatment-emergent
motor syndromes in native (Black) Africans with first episode
schizophrenia.
In the present study, which is based on a homogenous
sample of Black Africans with first episode schizophrenia, we
investigated the association between spontaneously occurring
NSS and EPS, with 3 months treatment-induced EPS after
exposure to minimum effective doses of flupenthixol decanoate.
METHODS
The present study is part of an investigation of the socio-
demographic, clinical, biological, and treatment aspects of
schizophrenia (and related disorders) in patients presenting for
biomedical treatment for the first time as out- or in-patients in
psychiatric hospitals and community clinics in Cape-Town South
Africa and Ibadan Nigeria. It was conducted by multidisciplinary
teams comprising of psychiatrists, mental health nurses, and
social workers at the two locations, and funded by the New
Partnership for Africa’s Development through the Department
of science and Technology of South Africa. Ethical approval was
obtained from the University of Ibadan ethics committee and the
Stellenbosch University Faculty of Medicine and Health Sciences
Human Research Ethics Committees. Participants provided
written, informed consent before interviews were conducted.
Subjects
The subjects comprised anti-psychotic naïve orminimally treated
patients with first episode schizophrenia or schizophreniform
disorder (5 subjects had a lifetime exposure to oral anti-
psychotics of less than 4 weeks). The diagnosis of the relevant
disorder was made according to criteria in the Diagnostic and
Statistical Manual for Mental Disorders-Fourth edition (DSM-
IV) (16) by the attending psychiatrist at the study locations.
Patients were eligible if they were aged between 16 and 45
years and have had less than 4 weeks of oral anti-psychotic
exposure during their life time. All eligible patients were
informed about the study, and the procedure was explained
to them in their home language. We excluded patients with
previous treatment of long acting depot antipsychotics, and
those meeting DSM IV criteria for current substance abuse. Also
excluded were patients with significant physical illnesses (e.g.,
chronic kidney disease) determined from the result of a full
physical examination and appropriate laboratory investigations.
Patients with mental retardation were excluded based on clinical
history. Additional formal testing of cognitive capacity was
not conducted. Participants comprised 81 Yoruba Nigerians, 18
Xhosa South-Africans. Participants did not receive monetary
compensation for their participation. They were evaluated as
far as possible before antipsychotic medications were prescribed.
The following information was obtained from all patients:
demographic data, personal history, psychiatric history, medical
history, family history.
Measures
The Structured Clinical Interview for the fourth edition of
the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV)- Patients edition (SCID-P) (17) was used in the
recruitment of patients. The SCID-P provides for a standardized
assessment that generates DSM-IV diagnoses using a semi-
structured interview.
Assessment of Neuromotor Abnormalities
Tests assessing NSS and EPS (described below) were
administered by independent raters (all psychiatrists) of
African (AO, BC, and OE), and Asian (LA) descent after a 3
weeks training at the Tygerberg Hospital, Cape-Town, South
Africa. Assessments were conducted in English and/or the
home language of participants. The inter-rater reliability (IRR)
conducted after training ranged from kappa= 0.62–0.82.
Neurological soft signs
NSS were evaluated using the Neurological Evaluation Scale
(NES) (18). The NES is a well validated tool for neurological
assessments in first episode schizophrenia. The scale includes
“functionally meaningful” sub-scales which reflect signs of
Motor co-ordination (tandem walk, rapid alternation, finger-to-
thumb opposition, and finger-to-nose test), Sensory integration
(audiovisual integration, stereognosis, graphesthesia, extinction,
and right-to-left confusion tests), and Motor sequencing (first-
ring, the first-edge-palm, Ozeretski, and rhythmic tapping tests).
The other signs assessed by the NES include cerebral dominance,
short-term memory, frontal release signs and eye movements.
The NES items are scored with reference to the descriptive
anchors provided on a three-point scale (no abnormality = 0;
mild, but definite impairment= 1; marked impairment= 2) with
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the exception of “suck” and “snout” reflexes which are scored 0
or 2. In this study, a neurological abnormality was defined as
the rating of 2 on any item (except cerebral dominance) on the
NES. Each item was assessed according to a fixed order. For the
present study, we considered the initial assessment of NSS before
introduction of antipsychotics.
Extrapyramidal syndromes
EPS were sassed using the Extrapyramidal Symptom Rating Scale
(ESRS) (19). The ESRS was designed to rate three main types
of EPS: Parkinsonism, dystonia and dyskinetic symptoms. The
measure also includes one question to cover akathisia. These
categories of EPS are measured assessed in three components of
the ESRS. A questionnaire and behavioral scale which includes
subjective questions covering the categories of EPS as follows:
Questions 1–5 and 7 (Parkinsonism), 6 (Akathisia), 8 (Dystonia),
and 10–11 (Dyskinesia). The status of each EPS is rated as
0 (if absent), 1 (mild), 2 (moderate), and 3 (severe). The
questionnaire component of the ESRS helps to differentiate
subjective akinesia from depressive symptoms related to the anti-
adrenaline effects of some antipsychotic drugs. But they also help
to differentiate akathisia from anxiety and psychotic agitation.
Also included in the ESRS are sections for physical examination
covering Parkinsonism, dystonia, and dyskinetic movements as
well as sections for clinical global impression items. The status
of EPS on clinical examination is rated as 0 (if normal), 1
(very mild), 2 (mild), 3 (moderate), 4 (moderately severe), 5
(severe), 6 (extremely severe). In line with previous studies
(20, 21), EPS was considered as present in this study where
there was a rating suggesting mild but definite extrapyramidal
sign or symptoms in the questionnaire scale (representing self-
reported EPS) or clinical examination (representing observed
EPS) components of the ESRS. The ESRS was administered
before exposure to antipsychotics, followed by 2 weekly ESRS
assessments throughout the duration of the study.
Psychiatric Assessment
The severity of the baseline psychopathology was evaluated
by administering the Positive and Negative Syndrome Scale
(PANSS) (22). The model of the PANSS adopted in this study
(23) included five factor analysis derived domain for “positive
symptoms” (delusions, hallucinations, unusual thought content,
suspiciousness, and grandiosity), “negative symptoms” (lack of
spontaneity, blunted affect, emotional withdrawals, apathetic
social withdrawals, motor retardation, poor rapport and
active social avoidance), “disorganization” (stereotyped thinking,
poor attention, disorientation, conceptual disorganization and
difficulty in abstraction), “excitement/hostility” (poor impulse
control, excitement, hostility, and uncooperativeness), and
“emotional distress” (anxiety, depression, guilt, and tension). The
PANSS five factor solution (23) was adopted for this study based
on its stability and superior validity when compared to the older
three factor model (22).
The overall clinical status was assessed using the Clinical
Global Impression (CGI-Severity) (24), while pre-morbid
adjustment was explored using the Pre-morbid Adjustment Scale
(PAS) (25). These measures have been used for the assessments of
African patients with schizophrenia in previous studies (26).
Duration of untreated psychosis (D.U.P) was defined as the
period in months from the onset of psychotic phenomena to
first presentation for biomedical treatment. Onset of psychosis
was defined as the presence for 1 week or more of psychotic
symptoms with marked deterioration of functioning.
In all cases, pre-morbid functioning was the retrospective
rating of patients’ functioning up to 6 months before the defined
onset of psychosis.
Treatment
After ruling out hypersensitivity by administering 1 milligram
(mg) of oral flupenthixol after the first assessment of clinical
and outcome characteristics, flexible doses of deep intramuscular
flupenthixol injections starting from 5 or 10mg in 2 or 4 weekly
intervals were administered, with increases by 5mg for up to a
maximum of 30mg depending on age, tolerability or response.
Depot antipsychotic was chosen for this study to rule out
covert non-adherence, a common phenomenon in first episode
schizophrenia (27).
Statistical Analysis
Descriptive statistics such as mean, median and standard
deviations were used to summarize quantitative variables, while
frequencies and proportions were used for discrete variables.
Spontaneous motor syndromes were those occurring before
first exposure to flupenthixol decanoate (28). Emergent EPS
was determined after exposure to flupenthixol decanoate and
censoring participants meeting criteria for spontaneous EPS. The
frequency and severity of spontaneous motor syndromes (NSS
and EPS) are presented along with their subcategories.
For the relationship between spontaneous motor syndromes
and treatment-emergent EPS, we first conducted a Pearson
correlation between spontaneous NSS and EPS total scores
with the scores for treatment-emergent EPS. Where significant
correlation coefficients were observed, the relevant spontaneous
motor syndrome scores (NSS or EPS) were entered as
independent variables into separate linear regression models.
Given previous observations that the frequency and severity
of motor syndromes in schizophrenia may be affected by both
premorbid adjustments and D.U.P (20), we conducted sub-group
analyses controlling for types of D.U.P (</≥12 months) and
premorbid adjustment (</≥mean for the entire sample).
Analyses were conducted using Stata version 13.0 (29). Values
of p < 0.05 were considered significant.
RESULTS
A total of 99 participants met study inclusion criteria and
underwent full baseline assessments (Figure 1). Table 1 shows
the baseline characteristics of the study sample. Never married
and unemployed young men, who were between the ages of
18 and 32 years at onset of psychosis, predominated in the
sample. They were mostly markedly ill with prominent positive
and disorganization psychopathologies. The median D.U.P was
approximately 2.5 years (Table 1).
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FIGURE 1 | Flow chart showing Spontaneous and Emergent Extrapyramidal
Syndromes (EPS) in the study of Black Africans with first episode
schizophrenia.
Table 2 describes the frequency and severity of spontaneous
motor syndromes and their relationship with 3-months
treatment-emergent EPS. About 91.8 and 20.2% of participants
had at least one definite spontaneous NSS and EPS respectively.
The only spontaneous motor syndrome not recorded in the
sample was dystonia. Newly emergent EPS was recorded
in 34 (38.6%) participants within 3 months of exposure
to antipsychotics. Whereas the overall domain scores of
spontaneous motor syndromes were not associated with
treatment emergent EPS, spontaneous dyskinesia was
significantly associated with treatment emergent akathisia
(r = 0.55, β = 1.65, p = 0.008). Table 2 also presents the
distribution of doses of flupenthixol decanoate. Antipsychotic
dose was not associated with treatment emergent motor
syndromes.
The results of analyses controlling for D.U.P and premorbid
adjustment is presented in Table 3. Spontaneous EPS was
associated with treatment-emergent Akathisia in participants
with a longer D.U.P (r = 0.75, β = 0.70, p = 0.008).

























Age at onset of Psychosis 25.5 (6.9)
Age at presentation 27.9 (6.6)
D.U.P in months, median 28.8 (46.5) 11.0
Neurological soft signs 18.0 (11.1)
Motor coordination 2.4 (2.1)
Sensory integration 4.7 (3.1)
Motor sequencing 5.2 (2.9)
Childhood premorbid adjustment 1.9 (2.8)/3.3 (2.7)
Adolescence premorbid adjustment 3.7(3.9)/3.4 (2.6)
Total PANSS scores 76.8 (18.5)
CGI-severity 5.1 (0.9)
Functioning (SOFAS) 44.6 (13.1)
D.U.P, Duration of untreated psychoses; P.A.S, Pre-morbid adjustment scale; PANSS,
Positive and Negative Syndrome Scale; CGI, Clinical Global impression; SOFAS, Social
and Occupational functioning scale.
This association was specific for Parkinsonism and dyskinesia
(Table 3). Conversely, spontaneous motor sequencing NSS
was associated with treatment-emergent dystonia (r = −0.99,
β = 1.89, p= 0.014).
DISCUSSION
The present study is based on a homogenous sample of
native (Black) Africans with first episode schizophrenia
or schizophreniform disorder. Our main finding was that
spontaneous EPS was associated with treatment emergent
akathisia. This relationship was especially evident when
considering spontaneous dyskinesia and Parkinsonism in
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TABLE 2 | Association of spontaneous motor syndromes with 3-months treatment induced extrapyramidal signs (EPS) assessed using the Extrapyramidal Symptom
Rating Scale (ESRS) after exposure to flupenthixol decanoate in Black Africans with first-episode schizophrenia.
Spontaneous motor syndromes (N = 99) 3-months treatment-emergent Extrapyramidal signs (Pearson
coefficients/βeta for linear regression)a
Neurological soft signs % Mean (SD) Parkinsonism Akathisia Dyskinesia Dystonia Overall
Sensory integration 45.9 2.4 (2.1) 0.11 0.20 0.36 0.05 0.13
Motor coordination 73.5 4.7 (3.1) 0.04 0.17 0.41 0.19 0.03
Motor sequencing 78.6 5.2 (2.9) 0.03 0.01 0.03 0.04 0.03
Total NES 91.8 18.0 (11.1) 0.06 0.17 0.09 0.11 0.07
EXTRAPYRAMIDAL SIGNS
Parkinsonism 18.2 0.71 (2.36) b 0.03 0.61 0.09 b
Akathisia 3.0 0.03 (0.17) b b b 0.03 b
Dyskinesia 3.0 0.10 (0.68) b 0.55*/1.65* b b b
Dystonia b b b b b b b
Overall 20.2 0.84 (2.46) b 0.13 0.61 0.09 b
Flupenthixol decanoate Minimun/Maximum Mean (SD)
Dose 5 mg/30mg 10.3 (2.27) 0.12 b b b 0.12
1. Participants were considered as having definite EPS in this study when they have a rating of ≥2 on the ESRS, 2. Percentages are based on the entire sample (N = 99), aParticipants
had definite EPS only after exposure to flupenthixol decanoate (i.e., had a score of <2 on the ESRS before exposure to treatment), bParticipants with treatment-emergent EPS but who
had a score of zero on the ESRS before exposure to flupenthixol decanoate, *p < 0.05.
patients with a longer D.UP. We also found an association
between spontaneous motor sequencing NSS and treatment-
emergent dystonia in patients with better premorbid
functioning.
Our finding suggesting that spontaneous motor syndromes
may predict treatment-emergent EPS are largely in keeping with
previous studies (10–12). Whereas we found that spontaneous
EPS is associated with treatment-emergent Akathisia, prior
studies implementing a longer term follow-up of up to 24
months have demonstrated this relationship for treatment-
emergent dyskinesia (13). Compared with dyskinesia, akathisia
is an earlier onset antipsychotic induced EPS (30). We have
implemented a short-term (3-months) follow-up in the present
study. This relatively short period of antipsychotic exposure
may have been insufficient to demonstrate large increases in
dyskinesia in our sample. For example, we found only 5
participants with treatment-emergent dyskinesia the present
study. This relatively small number may have been insufficient
to power a significant relationship for dyskinesia even if it
exists in our sample. Even so, our finding with respect to
akathisia is important as it shows that, as with dyskinesia,
spontaneous EPS may also predict the emergence of earlier
onset antipsychotic-induced EPS. This finding may also be
of value for the prevention of akathisia-linked psychomotor
agitation in clinical samples through the early identification
of susceptible patients. A future longer-term follow-up of our
sample will be needed to investigate whether as in other
populations, spontaneous motor syndromes predict treatment
emergent dyskinesia in Black Africans with first episode
schizophrenia.
Our finding of an association between spontaneous motor
sequencing NSS and treatment-emergent dystonia in patients
with better premorbid functioning was unexpected and must
be interpreted with caution. However, it is feasible that such
unpredictable findings suggest that there are more complex
relationships between the diverse neuromotor abnormalities in
schizophrenia. For example, it is plausible that spontaneous and
emergent motor syndromes represent distinct, and potentially
different, aspects of schizophrenia. This proposition is in keeping
with the findings of distinct structural and functional changes
(in the basal ganglia, pre-frontal and temporal cortices, as
well as the cerebellum) in relation to the clinical spectrum
of neuromotor abnormalities in schizophrenia (31, 32). Even
so, the aforesaid association between spontaneous motor
sequencing NSS and treatment-emergent dystonia in patients
with better premorbid functioning may well have occurred
by chance.
Strengths and Limitations
This study is based on a homogenous sample of Black Africans
with first episode schizophrenia. Given previous observations
that race may be important in determine putative risk
for neuromotor abnormalities in schizophrenia (14, 15), the
evidence provided by the present study is important for better
understanding of the nature of neuromotor disturbances of
schizophrenia. Prior information on neuromotor abnormalities
in schizophrenia, including their evolution in relation to
treatment has been based on mostly Caucasian or Mixed
population (10, 12, 21). A key limitation of the present study
is that the ESRS, which we have used for the ascertainment of
EPS, does not provide a robust evaluation of all EPS and is more
weighted toward Parkinsonism compared with, for example,
Akathisia.
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TABLE 3 | Relationship of spontaneous and 3-months treatment induced motor syndromes adjusted by duration of untreated psychosis and Premorbid adjustments in
Black Africans with first-episode schizophrenia.
Spontaneous motor
syndromes
3-months treatment-emergent Extrapyramidal signs (Pearson coefficients/βeta for linear regression)a
Duration of untreated Psychosis <12 months Duration of untreated Psychosis ≥12 months
Neurological soft
signs
Parkinsonism Akathisia Dyskinesia Dystonia Overall Parkinsonism Akathisia Dyskinesia Dystonia Overall
Sensory integration 0.11 0.62 0.95 0.93 0.11 0.06 0.07 b 0.37 0.05
Motor coordination 0.35 0.58 0.00 0.36 0.39 0.26 0.11 b 0.18 0.28
Motor sequencing 0.41 0.16 0.72 0.93 0.40 0.28 0.18 b 0.33 0.30
Total NES 0.35 0.43 0.73 0.97 0.39 0.13 0.06 b 0.26 0.16
EXTRAPYRAMIDAL SIGNS
Parkinsonism b 0.29 0.50 0.27 b b 0.75*/0.85* b 0.10 b
Akathisia b b b b b b b b 0.61 b
Dyskinesia b b b b b b 0.75*/1.70* b b b
Dystonia b b b b b b b b b b
Overall b 0.29 0.50 0.27 b b 0.75*/0.57* b 0.00 b
Good premorbid adjustment Poor premorbid adjustment
Sensory integration 0.21 0.08 b 0.80 0.23 0.01 0.15 0.36 0.80 0.02
Motor coordination 0.24 0.23 b 0.94 0.23 0.26 0.42 0.41 0.45 0.29
Motor sequencing 0.37 0.14 b 0.99*/1.89* 0.33 0.15 0.39 0.03 0.82 0.17
Total NES 0.22 0.23 0.09 0.90 0.23 0.07 0.24 0.09 0.74 0.09
EXTRAPYRAMIDAL SIGNS
Parkinsonism b 0.34 b 0.08 b b 0.15 0.61 0.24 b
Akathisia b b b b b b b b 0.58 b
Dyskinesia b 0.56 b b b b b b b b
Dystonia b b b b b b b b b b
Overall b 0.42 b 0.08 b b 0.15 0.61 0.11 b
1. Participants have poor premorbid adjustment when their score on the premorbid adjustment scale is less than the mean score for the entire sample, 2. Participants were considered
as having definite EPS in this study when they have a rating of ≥2 on the ESRS (suggesting definite EPS), 3. Percentages are based on the number entire sample (N = 99), aParticipants
who record definite EPS for the first time after exposure to flupenthixol decanoate, bParticipants with treatment emergent EPS but who had a score of zero on the ESRS before exposure
to flupenthixol decanoate, *p < 0.05.
CONCLUSION
Spontaneous EPS is predictive of treatment-emergent akathisia
during a relatively short period of follow-up. The findings overlap
with those of a previous 24 months longitudinal observation in
a mixed population of Africans where, given the long period
of observation, the relationship between spontaneous motor
syndrome and treatment-induced dyskinesia was discernible.
The result of the present study is of value for prevention
of akathisia-linked psychomotor agitation in clinical samples
through the early identification of susceptible patients. A future
longer-term follow-up of our homogenous sample of Black
Africans with first episode schizophrenia will investigate whether
as in other populations, spontaneous motor syndromes predict
treatment emergent dyskinesia in this population.
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